Bimatoprost

證據等級: L5

預測適應症: 10 個

Bimatoprost: From Glaucoma / Ocular Hypertension to Malformation Syndrome with Odontal and/or Periodontal Component

One-Sentence Summary

Bimatoprost is a synthetic prostamide F2α analog originally approved for reducing intraocular pressure in open-angle glaucoma and ocular hypertension, and subsequently for promoting eyelash growth (hypotrichosis). The TxGNN model predicts it may be effective for malformation syndrome with odontal and/or periodontal component, with 0 clinical trials and 20 publications currently retrieved — however, all retrieved literature consists of general periodontology papers and none directly addresses bimatoprost in this context.

Quick Overview

Item	Content
Original Indication	Open-angle glaucoma / Ocular hypertension (based on known pharmacology; India regulatory data unavailable)
Predicted New Indication	Malformation syndrome with odontal and/or periodontal component
TxGNN Prediction Score	99.999%
Evidence Level	L5
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacology, Bimatoprost is a synthetic prostaglandin F2α (prostamide) analog that reduces intraocular pressure by increasing uveoscleral and trabecular outflow of aqueous humor. It is approved as an ophthalmic solution for glaucoma (Lumigan™) and as a cosmetic eyelash-enhancing agent (Latisse™), the latter leveraging its hair follicle-stimulating properties by extending the anagen phase of the hair cycle.

Prostaglandins and their analogs are known to participate in bone remodeling and inflammatory signaling — both relevant biological pathways in periodontal disease. Specifically, prostaglandin E2 (PGE2) and related prostanoids are implicated in alveolar bone resorption and periodontal ligament inflammation. It is conceivable that a prostamide analog such as bimatoprost could modulate prostaglandin receptor activity in periodontal tissues, potentially influencing tissue homeostasis or malformation-related defects in the odontal-periodontal complex.

However, this mechanistic extrapolation is entirely hypothetical at this stage. The TxGNN model’s high prediction score likely reflects graph-based proximity in the knowledge graph between prostanoid signaling nodes and periodontal disease nodes — not established clinical or preclinical evidence. The 20 retrieved PubMed publications are standard periodontology references (guidelines, reviews, observational studies) with no mention of bimatoprost, confirming the absence of a direct evidence chain. This prediction warrants mechanistic investigation before any development resources are committed.

Clinical Trial Evidence

Currently no related clinical trials registered for bimatoprost in malformation syndrome with odontal and/or periodontal component.

Literature Evidence

The following publications were retrieved for the combined query of Bimatoprost and periodontal/odontal malformation. Important note: None of these publications directly address bimatoprost; they represent general periodontology literature returned by the evidence pipeline. They are listed here for context on the target disease landscape.

PMID	Year	Type	Journal	Key Findings
35688447	2022	Guideline	J Clin Periodontology	EFP S3-level clinical practice guideline for Stage IV periodontitis — covers severity, functional sequelae, and treatment recommendations
35420698	2022	Systematic Review	Cochrane Database	Periodontal treatment for glycaemic control in diabetes; evidence for bidirectional relationship between periodontitis and metabolic disease
29291254	2018	Systematic Review	Cochrane Database	Supportive periodontal therapy (SPT) reduces re-infection risk and maintains dentition following active treatment
39233377	2024	Review	Periodontology 2000	Obstructive sleep apnea identified as emerging risk factor for periodontal health
38907216	2024	Review	J Nanobiotechnology	Biomaterial-mediated macrophage immunotherapy as a novel direction in periodontitis treatment
38362600	2024	Cohort Study	J Dental Research	Periodontal therapy reduces oral-gut microbial dysbiosis in Stage III/IV periodontitis patients
37435999	2023	Review	Periodontology 2000	Complications and treatment errors in regenerative periodontal surgery
36883660	2023	Review	J Dental Research	Gingival fibroblasts act as innate immune sentinels in periodontitis pathogenesis
22057194	2012	Review	Diabetologia	Diabetes approximately triples susceptibility to periodontitis; two-way relationship well established
20599785	2010	Review	Biochemical Pharmacology	Complement system overactivation linked to periodontal immunopathology — potential target for anti-inflammatory intervention

India Market Information

Bimatoprost is currently not marketed in India. No regulatory authorizations have been identified in the India drug registry. The drug is approved in other jurisdictions (e.g., US FDA approval for Lumigan™ and Latisse™; EU/EMA approval), meaning international reference data may be consulted for regulatory strategy, but a full India CDSCO registration process would be required.

Safety Considerations

Drug Interactions: A total of 66 drug-drug interactions have been identified via the DDinter database. All are currently classified as Unknown severity, indicating that interaction magnitudes are not yet quantified. Notable interacting drugs include:

Metformin, Rosiglitazone (antidiabetics)
Simvastatin (lipid-lowering)
Prednisone, Prednisolone, Triamcinolone (corticosteroids)
Morphine, Loperamide (opioid/opioid-related)
Ondansetron, Palonosetron, Dolasetron (5-HT3 antagonists)
Vancomycin (antibiotic)
Omeprazole, Lansoprazole, Pantoprazole (proton pump inhibitors)

The clinical significance of these interactions in a topical or systemic repurposing context for periodontal disease would require dedicated pharmacovigilance review.

For key warnings and contraindications, please refer to the package insert, as these data were not available in the current evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a very high TxGNN model prediction score (99.999%), there is no direct preclinical or clinical evidence linking bimatoprost to malformation syndromes involving odontal and/or periodontal tissues. All 20 retrieved publications are general periodontology literature with no mention of bimatoprost. The mechanistic rationale — based on prostanoid signaling in bone and periodontal inflammation — is biologically plausible but entirely speculative at this stage.

To proceed, the following is needed:

Mechanism of action verification: Confirm whether bimatoprost’s prostamide receptor activity (FP receptors, prostamide receptors) is expressed in periodontal ligament, gingival fibroblasts, or alveolar bone cells
Preclinical proof-of-concept: In vitro or animal studies testing bimatoprost on periodontal tissue models or odontal malformation-related cell lines
Safety data: Retrieve full package insert for Lumigan™/Latisse™ to document contraindications, key warnings, and systemic exposure risks
Drug interaction clarification: Evaluate the 66 DDinter interactions of “Unknown” severity to identify any clinically significant risks in the target patient population
India regulatory pathway: Assess CDSCO requirements for a new drug with zero existing India market presence — including whether a new drug application (NDA) or bridging studies would be required
Literature gap analysis: Commission a systematic literature search specifically combining bimatoprost with prostaglandin receptor signaling in periodontal tissue to determine whether any indirect mechanistic evidence exists
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.